Crossmark

Effect and safety of tislelizumab combined with anlotinib and radiotherapy in advanced hepatocellular carcinoma: A single-arm, single-center, phase II clinical study

Crossref DOI link: https://doi.org/10.1038/s41598-026-55609-3

Published Online: 2026-05-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fan, Huaxi

Liu, Yuhong

Wu, Guishu

Rao, Mingyue

Zhang, Jing

Zhu, Peipei

Zhang, Jianwen
Clinical Trials ^BETA

Clinical trials referenced in this document:

chictr2000039022 at Chinese Clinical Trial Registry

Documents that mention this clinical trial

Effect and safety of tislelizumab combined with anlotinib and radiotherapy in advanced hepatocellular carcinoma: A single-arm, single-center, phase II clinical study
https://doi.org/10.1038/s41598-026-55609-3
License Information

Text and Data Mining valid from 2026-05-28

Version of Record valid from 2026-08-07
More Information

Article History

Received: 8 November 2025

Accepted: 26 May 2026

First Online: 28 May 2026

Declarations

Competing interests: The authors declare no competing interests.

Ethics approval: The study followed the Helsinki Declaration, and approved by the Institutional Review Board and Ethics Committee of the Affiliated Hospital of Southwest Medical University (9/8/2020/, KY2020135).

Patient consent statement: Informed consent was obtained from all subjects involved in the study.

Document is current

Any future updates will be listed below